Fellow multiple myeloma surivor, Nebraskan Jim Omel, is one of the smartest guys I know. A retired physician, Jim works tirelessly to help his fellow patients. Readers often ask me if it matters when they take their dexamethasone. Scheduled to start consolidation therapy this week, I’ve been wondering about it, too.
My good friend from north of the border, Nancy Shamanna, asked me to share this link to a survey for patients that have taken daratumumab (Darzalex). She’s hoping a positive response might move Canadian officials to adopt the new immunotherapy sooner rather than later:
I had an opportunity to interview several Takeda Pharmaceutical team members about the company’s new oral, proteasome inhibitor, Ninlaro (ixazomib), yesterday afternoon.
Following the news that not one but two new myeloma therapies are newly FDA approved, is it possible that the diabetes drug, meformin, could be a third? Before I post the fourth installment of Danny Parker’s series, I wanted to update everyone about how I’m holding up.
By most accounts, ixazomib (trade name, Ninlaro) should work as well or even better than Velcade. Preliminary reports are hopeful that adverse side effects may be fewer and more tolerable, too. “But storm clouds on the horizon?”
The FDA approved Takeda’s oral proteasome inhibitor, ixazomib, late this morning. First daratumumab on on Monday and now ixazomib today.
According to officials at the FDA, yesterday “the U.S. Food and Drug Administration granted accelerated approval for Darzalex (daratumumab) to treat patients with multiple myeloma who have received at least three prior treatments.”
I expected daratumumab to garner FDA approval sometime after ASH. So when I saw a news alert earlier today announcing that Darzalex had been approved, I didn’t pay any attention. But it didn’t take long for me to figure out that Darzalex is the new trade name for daratumumab. By any name, this is wonderful […]
Remember the good news that Mike from North Carolina shared with us last month?
Reader celebrating great response to daratumumab
Here’s an update about how I’m doing.
I’m often said our readers are my best resource. Early reports about the new immunotherapy, daratumumab, have been good. Mike, from North Carolina, recently enrolled in a dara trial. He emailed me about how great it’s working for him and agreed to share an email he sent his friends, trumpeting the early results. Here’s a […]
What did I do while I was stuck in Iowa waiting for test results and harvesting my stem cells? I updated two of my books, New Myeloma Therapies from a Patient’s Perspective, and Financial Aid for Myeloma Patients and Caregivers. The New Therapies book has shipped and is ready for sale.
Say it ain’t so! Don’t get diagnosed with multiple myeloma in England, Northern Ireland, Scotland or Wales. New austerity measures could result in an early death sentence for our brothers and sisters with myeloma in the UK. I wasn’t planning to write about this today, but I became so upset after reading an article on […]
As promised, here’s a comprehensive list of drugs and supplements that readers use to help battle peripheral neuropathy (PN) symptoms:
Important news as the promising new immunotherapy, daratumumab, continues to move swiftly toward FDA approval.
Common peripheral neuropathy (PN) remedies not working for you? Or maybe you’d like to try something new in addition to steps you’ve already taken to control symptoms. Here are additional suggestions made by fellow patients:
As promised, here are more ways to help minimize side effects of peripheral neuropathy (PN).
Dr. Tricot chose to administer CcD every other week, so my bone marrow would have time to recover between cycles. I started round two of my Cytoxan/Kyprolis/dexamethasone (CcD) yesterday afternoon. If you recall, the combination really wiped me out two weeks ago.
Such a simple abstract, with so many lessons to learn. Example of how Cytoxan and dex–at low doses–helped a relapsed patient in kidney failure stay stable for almost two years:
Long-term Control in a Patient with Refractory Multiple Myeloma by Oral Cyclophosphamide and Dexamethasone